Keting Chu

Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA.

Arkin Holdings engages in the provision of healthcare investment services which specializes in pharmaceutical and biotechnology, medical devices, dermatology, and hedge fund. The company was founded by Mori Arkin in 2009 and is headquartered in Herzliya, Israel.

Sequre Dx, Inc. is a genomics intelligence company that focuses on advancing on-target gene editing and cell therapies from discovery to patient. The company is based in Waltham, MA. The company offers preclinical platforms for the biopharma industry, including diagnostic assays and bioinformatic analytics that solve preclinical off-target evaluation needs. Sequre Dx aims to make gene editing and cell therapies suitable for all patients who would benefit from these life-saving technologies. The CEO of the company is Ellen E. Sheets.

Biolinq, Inc. develops skin-applied electronic sensors that analyze body fluids to provide health information. The company was founded by Jared Tangney and Josh Windmiller in 2012 and is headquartered in San Diego, CA.

Part of Xilio Therapeutics, Inc., Xilio Therapeutics LLC develops cancer biopharmaceuticals. The company is based in Waltham, MA. The CEO of the company is René Russo.

Scout Bio, Inc. operates as a biotechnology company that focuses on the innovation of pet medicine by delivering a pipeline of one-time therapeutics for major chronic pet health conditions. It also specializes in gene therapy, veterinary product development and biotechnology investment. The company was founded by James M. Wilson in 2016 and is headquartered in Philadelphia, PA.

Lutris Pharma Ltd. is working on the improvement of the anti-cancer therapy effectiveness and the quality of life for patients that are treated with Epidermal Growth Factor Receptor Inhibitors. The company was founded on December 14, 2015 and is headquartered in Tel Aviv, Israel.

Arkin Bio Ventures (Arkin Bio) is a venture capital arm of Arkin Holdings founded in 2016. The firm is headquartered in Tel Aviv, Israel.

RiverVest Venture Management LLC (RiverVest Venture Partners) is a venture capital firm founded in 2000 by Tom C. Melzer, Jay W. Schmelter, Mark J. Mendel and Andrew B. Craig III. The firm is headquartered in St. Louis, Missouri with additional offices in San Diego and Cleveland.

Integra Holdings Ltd. operates as a holding company. It invests in the pharmaceutical industry. The company was founded in 2012 and is headquartered in Jerusalem, Israel.

Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA.

Photys Therapeutics, Inc. is a company based in Cambridge, MA that was founded by Longwood Fund and Dr. Amit Choudhary of Brigham and Women's Hospital and the Broad Institute of MIT and Harvard. The company is advancing phosphorylation inducing chimeric small molecules (PHICs), a proprietary new class of bifunctional medicines that direct and repair protein phosphorylation to treat a range of diseases including cancer, immune, metabolic, and rare diseases. PHICs enhance the pairing of specific kinases with disease target proteins, inducing precise phosphorylation at native and/or non-native sites, modulating key functions including activation, stabilization, trafficking, localization, phospho-antigen presentation, inactivation, degradation, and interactions of proteins. The company's approach unlocks diverse classes of targets, developing a new class of medicines for precise control of protein function. The company was founded by Amit Choudhary, David Steinberg, Edward Holson, Lizzie Ngo. David Steinberg has been the CEO since incorporation.

Locki Therapeutics Ltd. is a British preclinical stage biotechnology company founded in 2019. The company is based in London, UK. Locki Therapeutics is developing a new class of drugs that enhance the function of beneficial proteins. The company has designed its proprietary encompass™ platform to create enhancement-targeting chimeric (entac™) medicines. These entacs harness the ability of dubs to regulate proteins, expanding the universe of treatable diseases.

Paros Bio, Inc. is a private company that specializes in gene therapy for neurodegenerative diseases. The company is based in Boston, MA. The company is focused on developing a gene replacement approach to treat autosomal dominant Alzheimer's disease (ADAD). Specifically, they are working on a gene therapy that targets mutations in the presenilin 1 gene (PSEN1), which is the underlying genetic cause of ADAD.

Entact Bio, Inc. is a company that focuses on creating new medicines by enhancing protein function. The company is based in Watertown, MA. The company is a team of scientists, entrepreneurs, drug creators, and problem solvers who work together to bring new medicines to patients who currently have few options. The CEO of the company is Victoria M. Richon. The founder of the company grew up in chaos and instability in an undisclosed capital city and has always been passionate and motivated to help enhance and provide medical solutions.

BVF Partners LP (BVF) is a SEC-registered investment advisor and hedge fund manager headquartered in San Francisco, California. The firm was founded in 1993 and is a subsidiary of BVF, Inc. BVF provides discretionary advisory services to private investment vehicles which includes commingled limited partnerships (the BVF Funds) and a limited liability entity organized for a single investor (Single Investor Fund) as well as to separately managed accounts.

Vedere Bio II, Inc. develops ocular gene therapy. The company is based in Cambridge, MA. The company was founded by Cyrus D. Mozayeni. Cyrus D. Mozayeni has been the CEO since incorporation.

Part of Nuvation Bio, Inc., AnHeart Therapeutics, Inc. is a clinical stage biopharmaceutical company based in New York, NY. AnHeart Therapeutics is focused on developing a pipeline of novel precision oncology therapeutics for areas of significant unmet medical need. The company's lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). AnHeart Therapeutics, Inc. also has a second investigational therapy, safusidenib, being evaluated in a phase 2 trial for -mutant glioma. AnHeart Therapeutics is supported by leading life sciences investors and has built an organization with deep oncology drug discovery and development expertise. The company was founded by Bing Yan, Junyuan Jerry Wang, Lihua Zheng, and the CEO is Junyuan Jerry Wang. AnHeart Therapeutics was acquired by Nuvation Bio, Inc. on April 09, 2024 for $89.30 million.

Octagon Capital Advisor/ Private Equity (Octagon Capital) is a private equity subsidiary of Octagon Capital Advisors LP founded in 2019 by Ting Jia. The firm is headquartered in New York.

HHLR Management Pte Ltd. (HHLR) is an alternative investment management firm headquartered in Singapore. The firm is a subsidiary of Hillhouse Capital Group Ltd. in Hong Kong. Formerly known as Hillhouse Capital Management Pte Ltd., HHLR provides investment solutions to institutional investors as well as to non-profit foundations.

Novartis Institute For Functional Genomics, Inc. serves as a bridge between basic science and preclinical drug discovery for Novartis’ global research organization. Its focus areas include oncology, autoimmunity, cardiovascular disease, diabetes, musculoskeletal disorders, and infectious disease. The company was founded in 1999 and is headquartered in San Diego, CA.

BioMed Ventures (BioMed Ventures) is a venture capital firm subsidiary of BioMed Realty founded in 2010. The firm is headquartered in San Diego, California.

Newyu, Inc. provides web-based health information services. It offers implementation, ongoing account management and customer support services. The company serves those monitoring asthma, diabetes, pulmonary disease, hypertension, cardiovascular disease and congestive heart failure. iMetrikus was founded by William J. Rutter in 1998 and is headquartered in Carlsbad, CA.

Ventria Bioscience, Inc. operates as a biopharmaceutical company. It offers Express Tec., a plant based recombinant protein supplement. The firm also offers controlling zoonotic disease and also provides access to its platform technology through contract manufacturing services. The company was founded by Raymond L. Rodriguez, Peter Matlock and William J. Rutter in 1993 and is headquartered in Fort Collins, CO.

Carnegie Institution of Washington is engaged in providing technical and scientific research services. The company was founded by Andrew Carnegie in 1895 and is headquartered in Washington, DC.

National Academy of Sciences operates as a private, nongovernmental institution that advises on issues related to science and technology. It provides independent, objective analysis and advice and conducts other activities to solve complex problems and inform public policy decisions. The firm also encourages education and research, recognize outstanding contributions to knowledge, and increase public understanding in matters of science. The company was founded on March 3, 1863 and is headquartered in Washington, DC.

Epitomics, Inc. an emerging biotechnology company, is dedicated to developing their breakthrough monoclonal antibody technology (RabMAb®) for research, diagnostics and therapeutics. The Company has utilized a unique and proprietary RabMAb technology invented by scientists at Loyola University of Chicago and the University of California at San Francisco. This enabling platform produces high quality antibodies that have the potetial to be used in the broad areas of research, diagnostics and therapeutics. Compared to currently available monoclonal antibody technology, such as mouse hybridomas, the company's proprietary technology can generate RabMAbs more efficiently and with superior binding affinity and bioactivity in a wide variety of biological assays. The high throughput and robust nature of the technology allows for the simultaneous discovery of disease targets and potential therapeutic antibodies in the same experiments, significantly shortening the drug discovery and development cycle. The company aims to become the largest provider of monoclonal antibody technology through developing and commercializing their RabMAb technology and products in research, diagnostics, and therapeutics. The firm is headquartered in Burlingame, California and operates a wholly owned subsidiary in Hangzhou, the People's Republic of China.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

Apexigen America, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. Its product portfolio includes humanized antibodies, targeting diseases such as cancer, inflammatory diseases and ophthalmic disease. The company was founded by Xiao Dong Yang in July 2010 and is headquartered in San Carlos, CA.

The American Academy of Arts & Sciences is an organization that honors excellence and brings together leaders. The non-profit company is based in Cambridge, MA.

Cell Works Group, Inc. engages in designing therapeutics with engineering precision. It also offers drug development and recycling and repurposing services. The company was founded by Shireen Vali, Pradeep Fernandes and Taher Abbasi in June 2005 and is headquartered in San Jose, CA.